The therapeutic potential of intranasally administered insulin via the nose-to-brain pathway is prominent for AD, as it reduces peripheral adverse events (e.g., interference with peripheral glucose homeostasis) by minimising the distribution of the drug in the systemic blood circulation [6, 7, 11, 12, 34]. The gene discussed is INS; the disease is Alzheimer disease.